INOVIO Pharmaceuticals, Inc. — Form 10-Q Summary
Business context and reporting period
Clinical-stage biopharmaceutical company developing DNA immunotherapies and vaccines delivered with proprietary electroporation technology. This unaudited 10-Q covers the quarter and nine months ended September 30, 2015; comparisons are with the same periods in 2014. No human-use product candidates had regulatory approval or product sales.
Financial performance and liquidity
| Metric | Q3 2015 | Q3 2014 | Nine months 2015 | Nine months 2014 |
|---|---|---|---|---|
| Revenue | $24.2 million | $1.8 million | $34.6 million | $8.0 million |
| Operating income (loss) | $3.7 million | ($8.3 million) | ($19.8 million) | ($28.5 million) |
| Net income (loss) | $5.6 million | ($7.2 million) | ($11.2 million) | ($28.7 million) |
| Net income (loss) per share, diluted | $0.07 | ($0.12) | ($0.18) | ($0.52) |
- Q3 operating and net margins were approximately 15% and 23%, respectively; nine-month operating and net margins were approximately negative 57% and negative 32%.
- At September 30, cash and cash equivalents were $85.5 million, short-term investments were $85.3 million, and working capital was $165.8 million. The filing reports no debt balance.
- For the nine months, operating cash use was $5.7 million (versus $21.7 million in 2014); investing cash use was $33.6 million, and financing provided $84.2 million. Cash and cash equivalents increased $44.9 million to $85.5 million.
- Total assets were $230.8 million, total liabilities $37.4 million, and accumulated deficit $343.1 million. The May equity offering raised $81.9 million net.
Material changes versus the prior comparable periods
- Revenue growth reflected the August 2015 MedImmune collaboration and higher grant revenue, including $7.3 million recognized from the DARPA Ebola grant in Q3. Nine-month collaboration revenue also included Roche-related revenue recognized after partial termination and a $3.0 million Roche milestone.
- MedImmune paid $27.5 million upfront. Inovio recognized $15.0 million for the INO-3112 license in Q3 and deferred $12.5 million allocated to research collaboration products and services.
- R&D expense rose to $16.1 million in Q3 and $42.2 million for nine months, from $7.0 million and $24.9 million, respectively, reflecting clinical studies, Ebola program work, headcount, and other development costs.
- Q3 2015 net income included a $1.8 million income-tax benefit and was affected by fair-value changes in warrants and affiliated investments. A $4.0 million unrealized gain on the PLS investment was reported in other comprehensive income, not net income.
Outlook, commentary, risks, and unusual items
- Management said existing cash and short-term investments were sufficient for planned working-capital needs for at least the next 12 months, while expecting continued substantial operating losses and possible future funding needs.
- MedImmune may pay up to $700 million in contingent development, regulatory, and commercial milestones; it will fund INO-3112 development. Inovio is also eligible for tiered royalties. These potential payments are contingent, not assured revenue.
- Roche ended its prostate-cancer collaboration for INO-5150; rights returned to Inovio. Collaboration on the hepatitis B candidate INO-1800 continues.
- Key risks include clinical and regulatory uncertainty, manufacturing and trial execution, reliance on collaborators and grants, and the need for additional capital. The company has no approved products and warns that clinical results may not predict later outcomes.
- The filing reports no material litigation. Management assessed disclosure controls as effective and reported no material change in internal control over financial reporting.
Most important facts for investors to verify
- Whether collaboration and grant revenue is repeatable, and how much of reported revenue is upfront, milestone-based, or tied to work performed.
- Progress and funding obligations under MedImmune and Roche agreements, including product selection, milestones, and any changes in collaboration scope.
- Cash burn, clinical-development spending, and the assumptions behind management’s at-least-12-month liquidity assessment.
- Clinical-trial results, regulatory progress, and the continued absence of approved products or product-sales revenue.